Clinical Trials on Plasma Lipids in Russian Federation

Total 166 results

University of Ulm
University of Pisa; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Medical... and other collaborators

Recruiting

Registry for Patients With Lipodystrophy (ECLip Registry)

Lipodystrophy Acquired | Lipodystrophy Congenital

Austria, France, Germany, Hungary, Italy, Portugal, Spain, Netherlands, Russian Federation, Slovenia, Switzerland, Turkey, United Kingdom
Sanofi

Recruiting

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Plasma Cell Myeloma

Czechia, Australia, Chile, France, Spain, United States, Brazil, China, Greece, Japan, Korea, Republic of, Sweden, Taiwan, Finland, Italy, Russian Federation
Alexion Pharmaceuticals

Completed

Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency

Lysosomal Acid Lipase Deficiency

Spain, Germany, Italy, United States, Croatia, Canada, Russian Federation, Denmark, United Kingdom, Belgium, Mexico, Australia, Netherlands, Brazil, Turkey
Abbott

Completed

Study to Assess Tricor Therapy Effectiveness in Patients With Metabolic Syndrome (TRISTAN) (TRISTAN)

Metabolic Syndrome | Hypertriglyceridemia

Russian Federation
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)

Hypercholesterolaemia

Netherlands, United States, Canada, Russian Federation, South Africa
Gilead Sciences

Terminated

A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)

Multiple Myeloma | Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia

United States, Czech Republic, Russian Federation
Oncopeptides AB

Terminated

Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma (LIGHTHOUSE)

Relapsed Multiple Myeloma | Relapsed-Refractory Multiple Myeloma

Serbia, Greece, Russian Federation, Czechia, Bulgaria, Georgia, Norway, Poland, Spain, Ukraine, Germany
Genzyme, a Sanofi Company

Completed

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)

Gaucher Disease, Type 1

United States, United Kingdom, Bulgaria, Canada, Colombia, India, Israel, Lebanon, Mexico, Russian Federation, Serbia, Tunisia
Abbott

Completed

A Prospective Observational Program Using Digital Technology Tools to Enhance Patient Adherence to Omacor Therapy (DIAPAsOn)

Hypertriglyceridemia | History of Myocardial Infarction

Russian Federation
Abbott

Completed

A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease

Dyslipidemia

Argentina, Czech Republic, Germany, Mexico, Poland, Romania, Russian Federation
Solvay Pharmaceuticals

Completed

Comparison of the Combination of Fenofibrate and Simvastatin Versus Pravastatin

Hyperlipidemia

Greece, Israel, Romania, Russian Federation, South Africa
AstraZeneca

Completed

Epanova® for Lowering Very High Triglycerides II (EVOLVE II) (EVOLVEII)

Hypertriglyceridemia

Denmark, United States, Hungary, Netherlands, Russian Federation, Czechia, Canada
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Terminated

The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy

Familial Partial Lipodystrophy

United States, Netherlands, Belgium, Brazil, Canada, Germany, Russian Federation
InSightec

Completed

ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain

Multiple Myeloma | Bone Metastases

United States, Canada, Israel, Italy, Russian Federation
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Atorvastatin Three Year Pediatric Study

Familial Hypercholesterolemia

United States, Spain, Turkey, Canada, Belgium, Germany, Greece, Hungary, Italy, Norway, Poland, Puerto Rico, Russian Federation, Slovakia, Switzerland
Shire

Completed

An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease

Gaucher Disease, Type 1

United States, Israel, Argentina, India, Korea, Republic of, Paraguay, Poland, Russian Federation, Spain, Tunisia, United Kingdom
Sanofi

Active, not recruiting

Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3 (ELIKIDS)

Gaucher's Disease Type III | Gaucher's Disease Type I

Canada, Argentina, France, Italy, Japan, Russian Federation, Spain, Sweden, Turkey, United Kingdom
Novartis Pharmaceuticals

Completed

A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia

Non Familial Chylocmicronemia Syndrome (Non-FCS)

United States, Canada, Russian Federation
Alexion Pharmaceuticals

Completed

Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency (ARISE)

Lysosomal Acid Lipase Deficiency

France, Poland, United Kingdom, Spain, Mexico, Turkey, Japan, Australia, Russian Federation, United States, Germany, Italy, Czechia, Argentina, Croatia
Amarin Pharma Inc.

Completed

Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL (MARINE)

Hypertriglyceridemia

United States, Netherlands, Russian Federation, Ukraine, Denmark, Finland, Germany, India, Italy, Mexico, South Africa
Takeda

Terminated

Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With Hypercholesterolemia

Hypercholesterolemia

Ukraine, Spain, Israel, Netherlands, Estonia, Russian Federation, Hungary, Norway, United Kingdom, Slovakia, Latvia
Amgen

Completed

Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia) (HAUSER-OLE)

Familial Hypercholesterolemia

Canada, Italy, Norway, Belgium, United States, Turkey, Australia, Austria, South Africa, Poland, Switzerland, Spain, Portugal, Slovenia, Brazil, Russian Federation, Hungary, United Kingdom, Colombia, Czechia, Netherlands, Greece, Ma...
Sanofi
Regeneron Pharmaceuticals

Completed

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

Hypercholesterolaemia

Czechia, France, Denmark, Netherlands, Austria, Mexico, Spain, United States, Argentina, Brazil, Bulgaria, Canada, Finland, Hungary, Italy, Lebanon, Norway, Poland, Russian Federation, Slovenia, South Africa, Sweden, Taiwan, Turkey
Genzyme, a Sanofi Company

Completed

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE) (ENCORE)

Gaucher Disease, Type 1

United States, France, Germany, Italy, Brazil, Australia, Argentina, Canada, Egypt, Russian Federation, Spain, United Kingdom
Janssen Research & Development, LLC

Completed

A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients

Multiple Myeloma

United States, Australia, France, Spain, Israel, India, Romania, Korea, Republic of, Singapore, Russian Federation, Poland
Sanofi

Active, not recruiting

Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients (IKEMA)

Plasma Cell Myeloma

France, United States, Australia, Brazil, Canada, Czechia, Greece, Hungary, Italy, Japan, Korea, Republic of, New Zealand, Russian Federation, Spain, Turkey, United Kingdom
Novartis Pharmaceuticals

Recruiting

Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Adolescent ORION-16 or ORION-13 Studies (V-PEDS-OLE)

Heterozygous or Homozygous Familial Hypercholesterolemia

Netherlands, Israel, Hungary, Italy, Germany, Turkey, Spain, United States, France, Norway, Russian Federation, South Africa, United Kingdom, Canada, Switzerland, Brazil, Lebanon, Slovenia, Poland, Taiwan, Malaysia
The Hospital for Sick Children

Active, not recruiting

International Rare Histiocytic Disorders Registry (IRHDR) (IRHDR)

Rare Histiocytic Disorders (RHDs) | Juvenile Xanthogranuloma (JXG) | Reticulohistiocytoma (Epithelioid Histiocytoma) | Xanthoma Disseminatum (XD) | Multicentric Reticulohistiocytosis (MRH) | Systemic Juvenile Xanthogranuloma | Erdheim-Chester Disease (ECD) | Multi-system Rosai-Dorfman Disease (RDD)

Canada, United States, Poland, Argentina, Austria, Czechia, Germany, Italy, Russian Federation, Spain
Takeda

Recruiting

A Study of Real Life Treatment for Multiple Myeloma (MM) (LEADER)

Multiple Myeloma

Russian Federation
Genzyme, a Sanofi Company

Active, not recruiting

A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of Venglustat in Late-onset GM2 (AMETHIST)

Tay-Sachs Disease | Sandhoff Disease

United States, Argentina, Czechia, Portugal, Russian Federation, Turkey, United Kingdom, Brazil, France, Germany, Italy, Japan, Spain
AstraZeneca

Completed

Epanova® for Lowering Very High Triglycerides (EVOLVE)

Severe Hypertriglyceridemia

United States, Hungary, India, Russian Federation, Denmark, Ukraine, Netherlands
Alexion Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis

AL Amyloidosis

United States, Germany, Spain, Russian Federation, France, Korea, Republic of, Poland, Israel, Netherlands, Japan, Belgium, Greece, Switzerland, Australia, Austria, Brazil, Canada, China, Czechia, Italy, United Kingdom
Sanofi

Active, not recruiting

Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant (IMROZ)

Plasma Cell Myeloma

Mexico, Sweden, Poland, France, Czechia, Greece, Taiwan, Lithuania, Portugal, Spain, Australia, Italy, New Zealand, Russian Federation, Turkey, Japan, United States, Belgium, China, Denmark, Germany
Genzyme, a Sanofi Company

Completed

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)

Gaucher Disease

United States, Sweden, India, Netherlands, Austria, Japan, China, Serbia, France, Croatia, Australia, Portugal, Canada, Brazil, Greece, Romania, Russian Federation
Alexion Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis

AL Amyloidosis

United States, Germany, Spain, United Kingdom, France, Korea, Republic of, Poland, Netherlands, Japan, Belgium, Greece, Australia, Austria, Brazil, Canada, China, Czechia, Israel, Italy, Russian Federation
Sanofi

Completed

Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients (ICARIA-MM)

Plasma Cell Myeloma

France, Spain, Greece, Korea, Republic of, United States, Australia, Belgium, Canada, Czechia, Denmark, Germany, Hungary, Italy, Japan, New Zealand, Norway, Poland, Portugal, Russian Federation, Slovakia, Sweden, Taiwan, Turkey, United...
Janssen Research & Development, LLC

Recruiting

A Study of Daratumumab

Multiple Myeloma

Korea, Republic of, United States, Russian Federation, Spain, France, China, Germany, Belgium, Denmark, Greece, Ukraine, Poland
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy (ODYSSEY FH I)

Hypercholesterolemia

United States, Austria, Canada, Czech Republic, Denmark, France, Israel, Netherlands, Norway, Russian Federation, South Africa, Spain, Sweden, United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia (ORION-16)

Familial Hypercholesterolemia - Heterozygous

United States, Germany, South Africa, Greece, Italy, Czechia, Taiwan, Slovakia, Turkey, France, Russian Federation, Canada, Spain, Jordan, Switzerland, Hungary, Poland, Netherlands, Norway, United Kingdom, Lebanon, Argentina, Brazil, ... and more
Boehringer Ingelheim

Completed

Combination of Telmisartan and Simvastatin in the Treatment of Hypertension and Hypercholesterolemia

Hypertension | Dyslipidemias

Taiwan, Netherlands, Czech Republic, France, Germany, Hong Kong, Korea, Republic of, Russian Federation, Slovakia, South Africa, Sweden, Ukraine
Amgen

Completed

Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders (HAUSER-RCT)

Heterozygous Familial Hypercholesterolemia

United States, Canada, Italy, Norway, Belgium, Turkey, Australia, New Zealand, Austria, Czechia, South Africa, Poland, Spain, Switzerland, Netherlands, Taiwan, Finland, Brazil, Portugal, Slovenia, Russian Federation, Hungary, United... and more
Amgen

Completed

A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma (FOCUS)

Multiple Myeloma

France, Poland, United Kingdom, Belgium, Germany, Spain, Israel, Serbia, Australia, Greece, Korea, Republic of, Russian Federation, Hungary, Sweden, Austria, Slovakia, Italy, Czechia, New Zealand
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)

Hypercholesterolemia

United States, Canada, Denmark, France, Hungary, Israel, Korea, Republic of, Russian Federation, South Africa, Ukraine
Kowa Research Europe

Completed

Long-Term Extension Study of Pitavastatin in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia

Dyslipidemia | Hypercholesterolemia

Spain, Denmark, India, Israel, Sweden, Finland, Germany, Italy, Netherlands, Norway, Poland, Russian Federation, United Kingdom
Kowa Research Europe

Completed

Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels

Dyslipidemia | Primary Hypercholesterolemia

Spain, Denmark, India, Israel, Sweden, Finland, Germany, Italy, Netherlands, Norway, Poland, Russian Federation, United Kingdom
Regeneron Pharmaceuticals

Completed

Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia

Hypercholesterolemia

United States, Spain, Australia, Netherlands, Japan, Jordan, Denmark, Israel, Sweden, South Africa, Canada, Austria, Czechia, France, Italy, New Zealand, Norway, Poland, Russian Federation, United Kingdom
Regeneron Pharmaceuticals
Sanofi

Terminated

Long Term Safety Study of PRALUENT

Heterozygous Familial Hypercholesterolemia | Non-familial Hypercholesterolemia

United States, Bulgaria, Estonia, Russian Federation, South Africa, Ukraine
Takeda

Completed

Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia

Dyslipidemia

United States, Germany, Argentina, Mexico, Poland, South Africa, Chile, Netherlands, Peru, Estonia, Russian Federation, Czech Republic, Hungary, Lithuania, Latvia, Slovakia, United Kingdom
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST 2)

Diabetes Mellitus, Type 2 | Dyslipidemia | Peripheral Vascular Disease | Coronary Arteriosclerosis | Cerebrovascular Accident

Greece, Ireland, Russian Federation, Slovakia, Poland, Hungary, Portugal, Switzerland
Janssen-Cilag Ltd.
Legend Biotech

Completed

A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment (LocoMMotion)

Multiple Myeloma

Belgium, United States, United Kingdom, Italy, Germany, Netherlands, Spain, France, Russian Federation, Poland

Clinical Trials on Plasma Lipids in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations